On August 7, 2024, Conduit Pharmaceuticals Inc. entered into a License Agreement with AstraZeneca AB, granting Conduit exclusive rights to develop and commercialize certain intellectual property for HK-4 Glucokinase activators and a myeloperoxidase inhibitor for idiopathic male infertility. The agreement includes an upfront payment of $1.5 million, common stock issuance, and tiered sublicense revenue sharing. Conduit will initiate Phase II clinical trials for the licensed compounds, which have already shown favorable preclinical and Phase I data. Additionally, Conduit amended a previous funding agreement with St George Street Capital, allowing for other third-party project funders. The License and Issuance Agreements will be filed with the SEC as part of Conduit's Quarterly Report for Q3 2024.

On August 7, 2024, Conduit Pharmaceuticals Inc. entered into a License Agreement with AstraZeneca AB, granting Conduit exclusive rights to develop and commercialize certain intellectual property for HK-4 Glucokinase activators and a myeloperoxidase inhibitor for idiopathic male infertility. The agreement includes an upfront payment of $1.5 million, common stock issuance, and tiered sublicense revenue sharing. Conduit will initiate Phase II clinical trials for the licensed compounds, which have already shown favorable preclinical and Phase I data. Additionally, Conduit amended a previous funding agreement with St George Street Capital, allowing for other third-party project funders. The License and Issuance Agreements will be filed with the SEC as part of Conduit's Quarterly Report for Q3 2024.